BioMarin Pharmaceutical Inc. (BMRN) shares rose 19.51%, climbing $10.13 to $62.08, after the company announced a definitive agreement to acquire Amicus Therapeutics for about $4.8 billion in cash.
The deal values Amicus at $14.50 per share, representing a significant premium to its recent trading price, and is expected to expand BioMarin's portfolio with key rare-disease therapies, including Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, thereby strengthening its commercial reach.
On the day of the announcement, BMRN opened near its previous close, rallied to an intraday high above $62, and saw unusually heavy trading volume, reflecting strong investor interest tied to the strategic acquisition.
BioMarin said the transaction is expected to accelerate revenue growth, diversify its rare-disease drug portfolio, and be accretive to earnings within the first year after closing, which is anticipated in the second quarter of 2026, subject to customary closing conditions.
52-Week Range: BMRN has shown significant volatility as pipeline data and corporate developments have influenced sentiment throughout the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.